St. Paul, Minn.-based St. Jude Medical earned Food and Drug Administration approval for its BurstDR stimulation technology, a physician-developed form of spinal cord stimulation used to treat patients with chronic pain.
Spinal cord stimulation uses an implant, placed near the spinal cord, to deliver mild electrical stimulation to the nerves along the spinal column to block pain messages from reaching the brain.
St. Jude's BurstDR stimulation uses intermittent bursts of electrical pulses to copy the body's natural nerve impulse patterns, according to the report.
Patients receiving stimulation implants from St. Jude will now have access to the new therapy and those already implanted with the devices will be able to upgrade their systems to administer BurstDR stimulation without additional surgery, the company said.
More articles on supply chain:
5 factors driving supply chain innovation
FDA approves Teva's generic HIV drug
Hospital bed company LINET buys majority stake in BORCAD Medical